An Open-Label, Dose Escalation, Phase 1 Study Of Mln4924
Open-Label, Dose Escalation, Phase I Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients w/ Acute Myelogenous Leukemia & High-Grade Myelodysplastic Syndrome | |
|---|---|
| Sponsor(s) | Millenium Pharma |
| Principal Investigator(s) | John Kauh, MD, Sagar Lonial, MD |
| Dates | 3/18/2008 - 3/31/2014 |
